1. Background {#sec109373}
=============

Hepatitis B virus (HBV) is a double-stranded DNA virus belonging to the *Hepadnaviridae* family. Hepatitis B is a potentially life-threatening liver disease caused by HBV. It is a major global health problem and the most serious type of viral hepatitis. It can cause chronic liver disease and put people at high risk of death from cirrhosis of liver and liver cancer ([@A20598R1]).

Perinatal transmission is one of the most common routs of HBV transmission worldwide ([@A20598R2]). Routine screening of pregnant women for hepatitis B surface antigen (HBsAg) is recommended by the World Health Organization ([@A20598R3]).

Chronic HBV infection affects approximately 350 million people worldwide, half of whom acquire the infection from perinatal transmission or in early childhood ([@A20598R4]). The prenatal transmission of HBV leads to severe long-term sequelae. Children born to HBsAg+ and HBeAg+ mothers have 70-90% chance of prenatal acquisition of HBV infection and over 85-90% of them will eventually become chronic carriers of the disease. Chronic carriers of HBV are main reservoirs for continued transmission of HBV and have a higher risk of hepatocellular carcinoma and liver cirrhosis. Many of them eventually become mothers themselves; thus, they perpetuate the cycle ([@A20598R5]). The screening of antenatal clinic attenders for HBV is a relatively routine practice in most health settings in Iran. Some studies have evaluated the prevalence of HBV among antenatal pregnant women. The prevalence rate of HBV among rural and urban pregnant women in Cameroon was reported 5.4% and 7.85%, respectively ([@A20598R6], [@A20598R7]).

Autoimmune hepatitis is a form of chronic hepatitis which affects the patients who have lost their immunological tolerance to liver-specific antigens and is more frequent in females and it may mimic chronic HBV ([@A20598R8]).

Hepatitis B vaccine was introduced via National Immunization Program (NIP) in Iran in 1993. Recombinant hepatitis B vaccines are available at primary care centers free of charge to any applicant. This program entails vaccination of all neonates at birth and routine immunization of high-risk groups. However, there continues to be little focus on the adult population and immigrant peoples ([@A20598R9]).

Since HBV is one of the leading causes of hepatocellular carcinoma (HCC), it is important to assess whether there has been a shift in the epidemiology of this condition over time. This will help the Ministry of Health for better policy making.

2. Objectives {#sec109374}
=============

The aim of this study was to determine the prevalence of HBsAg among pregnant women attending Beheshti Hospital of Kashan, Iran in 2012.

3. Patients and Methods {#sec109375}
=======================

This was a cross-sectional study on pregnant women, hospitalized in the Obstetric Ward from December 2011 to January 2012 in Beheshti Teaching Hospital in Kashan-Iran. Kashan is a small city in Isfahan province. Ethical approval to conduct this study was obtained from the ethical committee of the Research Deputy of Kashan University of Medical Sciences with code No. 1679. The study recruited 768 pregnant women attending to the Obstetric Ward of Beheshti Hospital due to any cases during the one year of the study.

Beheshti Hospital is a major general hospital with all types of specialists and sub-specialists, except for ear, nose and throat (ENT) and ophthalmology ward, with 12 wards and 500 beds.

The sample size was calculated using the standard formula for sample size calculation: N = z^2^pq/d^2^ (where z = the standard normal deviation at 1.96 (which corresponds to a 95% confidence interval), p = the prevalence of hepatitis B in general Iranian population, q = 1 -- p; d = the degree of precision expected to be 0.05).

Sampling was systematically randomized by using the list of patients attending to obstetric and prenatal care clinics of Beheshti Hospital, the information of whom were recorded in Health Information System (HIS) of the hospital. All the cases were visited by a gynecologist and then referred to an infectious disease specialist. Clinical variables were measured though history taking and clinical examination by an intern observer.

The inclusion criteria were positive pregnancy test and written informed consent. Each woman who refused to give consent was excluded. After obtaining the consents, all the participants were interviewed by an interviewer. According to the inclusion criteria, 800 subjects were included and then 32 were excluded. At first, the advantages of the test were explained for the participants and the consent forms were obtained.

A questionnaire including socio-demographic information and HBV infection-associated risk factors, such as a previous history of blood transfusion, history of previous jaundice, a history of tattooing, contact with a person with known history of hepatitis B infection or jaundice, was filled. Afterwards, 5 mL blood was aseptically taken from each patient and the blood specimens were transmitted to a laboratory. At the laboratory, after plasma separation, test for HBsAg using the Monalisa HBsAg ultra ELISA kit was performed. We used statistical package for social sciences (SPSS) version 16.0 software. Simple descriptive statistics such as mean and standard deviation were used to describe the data, as appropriate. We tested the associations between categorical variables using the chi-squared, ANOVA and leren, and Fischer's exact tests, reporting the corresponding P values.

4. Results {#sec109376}
==========

Among the 768 patients, the ages varied between 15 and 45 years with a mean of 24.65 ± 4.03 years (min = 21 and max = 39). The majority of cases were in the age group of 20-28 years. The statistical test for comparing the age between the two groups showed no significant difference (P = 0.23). HBsAg was detected in the plasma of 12 women, giving an overall HBsAg prevalence of 1.56%. The mean age among the pregnant women who were HBsAg+ was 26.9 years. The prevalence of HBsAg was the highest among the 25 - 29-year-old group ([Table 1](#tbl28064){ref-type="table"}). There was no statistically significant association between the socio-demographic characteristics evaluated and the HBsAg status.

###### Socio-Demographic Characteristics and Hepatitis B Virus Infection Infection-Related 148 Risk Factors of Pregnant Women ^[a](#fn27296){ref-type="table-fn"},[b](#fn27297){ref-type="table-fn"}^

  Characteristic                         Total         HBsAg+ ^[a](#fn27296){ref-type="table-fn"}^   HBsAg- ^[a](#fn27296){ref-type="table-fn"}^   Statistical Test
  -------------------------------------- ------------- --------------------------------------------- --------------------------------------------- ------------------
  **Level of education**                                                                                                                           0.01
  Under high school diploma              134 (17.44)   8 (1)                                         126 (16.44)                                   
  High school diploma and higher         634 (8.55)    4 (0.5)                                       630 (82.05)                                   
  **Residence**                                                                                                                                    0.59
  Urban                                  632 (82.29)   8 (1)                                         624 (81.29)                                   
  Rural                                  136 (17.7)    4 (0.5)                                       132 (17.2)                                    
  **Nationality**                                                                                                                                  0.001
  Iranian                                632 (82.29)   2 (0.26)                                      630 (82)                                      
  Non-Iranian                            136 (17.7)    10 (1.3)                                      126 (16.4)                                    
  **Job**                                                                                                                                          P \> 0.999
  High-risk                              16 (2)        0                                             16 (2)                                        
  Other                                  752 (98)      12 (1.5)                                      740 (96.5)                                    
  **Gestational age**                                                                                                                              P \> 0.999
  First trimester                        \-            \-                                            \-                                            
  Second trimester                       4 (0.5)       0                                             4 (0.5)                                       
  Third trimester                        764 (99.5)    12 (1.5)                                      752 (98)                                      
  **History of abortion**                                                                                                                          0.056
  Yes                                    160 (20.83)   6 (0.78)                                      144 (20)                                      
  No                                     608 (79.16)   6 (0.78)                                      602 (78.3)                                    
  **History of tattooing**                                                                                                                         P \> 0.999
  Yes                                    44 (5.72)     0                                             44 (5.72)                                     
  No                                     724 (94.27)   12 (1.5)                                      712 (92.77)                                   
  **History of hepatitis or jaundice**                                                                                                             P \> 0.999
  Yes                                    44 (5.72)     0                                             44 (5.72)                                     
  No                                     724 (94.27)   12 (1.5)                                      712 (92.77)                                   
  **History of transfusion**                                                                                                                       0.01
  Yes                                    68 (8.8)      6 (0.78)                                      62 (8)                                        
  No                                     700(91.14)    6 (0.78)                                      694 (90.3)                                    
  **History of dentistry procedure**                                                                                                               P \> 0.999
  Yes                                    68(8.8)       0                                             68(8.8)                                       
  No                                     700 (91.14)   12 (1.5)                                      688 (89.64)                                   
  **HBV vaccination of husband**                                                                                                                   0.01
  Yes                                    732 (82.29)   4 (0.5)                                       628 (81.8)                                    
  No                                     136 (17.7)    8 (1)                                         128 (16.7)                                    
  **HBsAg of husband**                                                                                                                             0.001
  Positive                               8(1)          8(1)                                          0                                             
  Negative                               760 (99)      4 (0.5)                                       756 (98.5)                                    

^a^ Abbreviations: HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.

^b^Values are presented as No (%).

5. Discussion {#sec109377}
=============

The results of our study indicated that the prevalence of HBsAg among pregnant women was 1.56%. Our results were however higher than earlier reports of HBsAg prevalence among pregnant women in Kashan by Tabbassi et al. who reported 0.35% HBsAg+ prevalence (seven HBsAg+ case out of 2000 pregnant women) in ten years ([@A20598R10]).

Studies in other countries have reported different rates of prevalence of HBsAg among pregnant women. The HBsAg prevalence among pregnant women was reported 8.3% by Luka et al. ([@A20598R11]) and Eke et al. ([@A20598R12]) in Nigeria. They are comparable with the 6.4% HBsAg prevalence reported in Ghana ([@A20598R13]), the 6.5% in Congo ([@A20598R14]), the 9.3% in Kenya ([@A20598R15]), the 10.7% in Burkina Faso ([@A20598R16]), and the 7.7% in Cameroon ([@A20598R5]). All these countries are generally considered the areas of hyperendemicity for hepatitis B infection (prevalence \> 8%).

The prevalence of HBsAg among pregnant women reported in other areas is as follows: Indonesia 4.7% ([@A20598R17]), France 7.2% ([@A20598R18]), Peru 9.38% ([@A20598R19]), Israel 0.88% ([@A20598R20]), Turkey 2.1% ([@A20598R21]), Eastern China 6.71% ([@A20598R22]), and 2.3% in Kerman, Iran ([@A20598R23]). Our findings were significantly lower than the prevalence of HBsAg reported by the abovementioned studies. On the contrary, our results were higher than the 0.35% HBsAg prevalence reported in a previous study among antenatal clinic attendants in Kashan ([@A20598R10]). Our results were comparable with the 1.5% prevalence in Tripoli, Libya ([@A20598R24]), but were higher than the 0.5% HBsAg prevalence reported in Isfahan and 1% in Gorgan, Iran ([@A20598R25], [@A20598R26]).

These differences of prevalence in different nationalities and minorities are related to the route of transmission more than genetic factors. The highest numbers of HBV-infected pregnant women in our study were immigrants from neighbor countries.

In our study, the mean age of HBsAg positivity was 24.65 ± 4.03 years and HBsAg was the highest among the 20 - 28-year-old group. In the study of Vasquez et al. and Fomulu et al. ([@A20598R5], 19), also, the average age of women infected with hepatitis B virus was 26 years. Our findings were somewhat in contrary with those of Ndumbe et al. in Cameroon ([@A20598R6]), and Eke et al. in Nigeria ([@A20598R12]) who found the highest prevalence of HBsAg among the 10 - 19-year-old age group (10.4%), and the 15 - 19-year-old age group (16.7%), respectively.

A possible reason for the slightly higher HBsAg prevalence in the 25 - 29-year-old age group is the fact that between these ages, many females are likely to get married and become pregnant. They are therefore likely to attend antenatal care centers for the first time, and thus, can be easily picked up by screening.

Other socio-demographic characteristics were evaluated to determine whether these were associated with a risk of HBV acquisition. These included the gestational age, job, history of transfusion, tattooing, jaundice and dentistry procedures. We did not find a statistically significant association between job, history of tattooing, jaundice, dentistry procedure, gestational age and the risk of HBV infection among our study subjects. There was significant statistical association between nationality, history of transfusion and infection in husband and the risk of HBV infection among our cases. It was noted from this study that previous contact with someone with hepatitis B infection was a statistically significant predisposing factor for HBsAg infection.

Our findings were in accordance with other reports indicating that the risk of HBV transmission was high in people in contact with chronically infected HBV subjects ([@A20598R12], [@A20598R27]). In reports from other studies, some of these factors may be linked with the risk of HBV acquisition. In the study of Fumulla, there was no statistically significant association between age or other socio-demographic risk factors and HBsAg status. Only a history of a contact with hepatitis B infection was found to be significantly associated with HBsAg positivity ([@A20598R5]). Kolawole in Osogbo, Nigeria found no significant difference in HBsAg positivity in relation to maternal age, gravidity, gestational age, family type, level of education and occupation (P = 0.073). There was significant difference in HBsAg just in history of HBV vaccination (P = 0.039) ([@A20598R1]).

The study of Ayatollahi et al. showed the high acceptance and compliance of hepatitis B vaccination among the tested group due to the opportunity of free vaccination offered by the healthcare provider. Lack of knowledge about hepatitis B infection and the importance of vaccination, fear of side effects, worries about privacy, perceived low risk for infection, and time were the reasons for vaccination rejection ([@A20598R9]). Therefore, encouraging the general population to voluntary HBV vaccination and obligatory vaccination of immigrant people can be a helpful method for prevention of transmission of HBV.

The major strength of our study was its large sample size. Patients were recruited prospectively and our results demonstrated the state of the epidemiology of HBV as it presently is. One of our limitations was that data on reported risk factors depended on the memories of the study participants and there was no other means to verify the truthfulness of this information. Moreover, it was noticed that the probing into these risk factors created an atmosphere of suspicion of HBV infection among the study participants and may have biased some of the responses.

According to the higher frequency of HBsAg+ cases among immigrant women, HBsAg test for screening should be performed in primary evaluation of pregnant women in this group in Iran. The inclusion of HBsAg as a routine prenatal and premarriage test should be accompanied by appropriate facilities for management of positive cases and prevention of HBV transmission through prenatal and sexual routes.
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